GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CV Sciences Inc (OTCPK:CVSI) » Definitions » Return-on-Tangible-Asset

CV Sciences (CV Sciences) Return-on-Tangible-Asset : -29.85% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is CV Sciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. CV Sciences's annualized Net Income for the quarter that ended in Mar. 2024 was $-2.51 Mil. CV Sciences's average total tangible assets for the quarter that ended in Mar. 2024 was $8.42 Mil. Therefore, CV Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -29.85%.

The historical rank and industry rank for CV Sciences's Return-on-Tangible-Asset or its related term are showing as below:

CVSI' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -97.65   Med: -49.99   Max: 43.11
Current: -34.33

During the past 13 years, CV Sciences's highest Return-on-Tangible-Asset was 43.11%. The lowest was -97.65%. And the median was -49.99%.

CVSI's Return-on-Tangible-Asset is ranked worse than
80.22% of 1082 companies
in the Drug Manufacturers industry
Industry Median: 1.83 vs CVSI: -34.33

CV Sciences Return-on-Tangible-Asset Historical Data

The historical data trend for CV Sciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CV Sciences Return-on-Tangible-Asset Chart

CV Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.46 -63.45 -76.45 -56.52 29.17

CV Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 192.59 -49.43 -18.80 -38.26 -29.85

Competitive Comparison of CV Sciences's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CV Sciences's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CV Sciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where CV Sciences's Return-on-Tangible-Asset falls into.



CV Sciences Return-on-Tangible-Asset Calculation

CV Sciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=3.102/( (12.485+8.78)/ 2 )
=3.102/10.6325
=29.17 %

CV Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-2.512/( (8.78+8.053)/ 2 )
=-2.512/8.4165
=-29.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


CV Sciences  (OTCPK:CVSI) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


CV Sciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of CV Sciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CV Sciences (CV Sciences) Business Description

Traded in Other Exchanges
Address
9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126
CV Sciences Inc is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). The company also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based novel therapeutics.
Executives
William Mccorkle director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Corroon James Michael Jr. director 9530 PADGETT STREET, SUITE 107, SAN DIEGO CA 92126
Maroon Joseph C Md director 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mona Michael Joseph Jr director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Paul Blake director 145 BRANDYWINE PKWY, WEST CHESTER PA 19380
Douglas Jesse Mackay officer: Sr VP Scientific/Regulatory 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Joseph D Dowling officer: Chief Financial Officer 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Joerg Grasser officer: CFO 2688 SOUTH RAINBOW BLVD STE B, LAS VEGAS NV 89146
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Terri F Graham director C/O JACK IN THE BOX INC, 9330 BALVOA AVE, SAN DIEGO CA 92123
Stephen Martin Schmitz director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Gary Sligar director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
James A Mcnulty director C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Larry Phillip Raskin director 1630 FUNNY CIDE DRIVE, WAXHAW NC 28173
Mackay Ventures Inc. other: Member 10% holding group 6325 S. JONES BOULEVARD #500, LAS VEGAS NV 89118